Miniatura

Fitxers

701727.pdf (343.3 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2019-09-01

Llicència de publicació

cc-by (c) Elez, Elena et al., 2019
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/177745

Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS-mutant metastatic colorectal cancer

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1002/1878-0261.12547

Resum

Despite major advances in the treatment of metastatic colorectal cancer (mCRC), the survival rate remains very poor. This study aims at exploring the prognostic value of RAS-mutant allele fraction (MAF) in plasma in mCRC. Forty-seven plasma samples from 37 RAS-mutated patients with nonresectable metastases were tested for RAS in circulating tumor DNA using BEAMing before first- and/or second-line treatment. RAS MAF was correlated with several clinical parameters (number of metastatic sites, hepatic volume, carcinoembryonic antigen, CA19-9 levels, primary site location, and treatment line) and clinical outcome [progression-free survival (PFS) and overall survival (OS)]. An independent cohort of 32 patients from the CAPRI-GOIM trial was assessed for clinical outcome based on plasma baseline MAF. RAS MAF analysis at baseline revealed a significant correlation with longer OS [Hazard ratios (HR) = 3.514; P = 0.00066]. Patients with lower MAF also showed a tendency to longer PFS, although not statistically significant. Multivariate analysis showed RAS MAFs as an independent prognostic factor in both OS (HR = 2.73; P = 0.006) and first-line PFS (HR = 3.74; P = 0.049). Tumor response to treatment in patients with higher MAF was progression disease (P = 0.007). Patients with low MAFs at baseline in the CAPRI-GOIM group also showed better OS [HR = 3.84; 95% confidence intervals (CI) 1.5-9.6; P = 0.004] and better PFS (HR = 2.5; 95% CI: 1.07-5.62; P = 0.033). This minimally invasive test may help in adding an independent factor to better estimate outcomes before initiating treatment. Further prospective studies using MAF as a stratification factor could further validate its utility in clinical practice.

Matèries

Sang, Genètica, Càncer colorectal, Mortalitat, Mutació (Biologia)

Matèries (anglès)

Blood, Genetics, Colorectal cancer, Mortality, Mutation (Biology)

Citació

Col·leccions

Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Citació

ELEZ, Elena, CHIANESE, Chiara, SANZ-GARCÍA, Enrique, MARTINELLI, Erica, NOGUERIDO, Alba, MANCUSO, Francesco mattia, CARATU, Ginevra, MATITO, Judit, GRASSELLI, Julieta, CARDONE, Claudia, ESPOSITO, Riziero esposito, MARTINI, Giulia, SANTOS, Cristina, MACARULLA, Teresa, ARGILÉS, Guillem, CAPDEVILA, Jaume, GARCIA, Ariadna, MULET MARGALEF, Núria, MAIELLO, Evaristo, NORMANNO, Nicola, JONES, Frederick, TABERNERO CATURLA, Josep, CIARDELLO, Fortunato, SALAZAR SOLER, Ramón, VIVANCOS, Ana. Impact of circulating tumor DNA mutant allele fraction on prognosis in RAS-mutant metastatic colorectal cancer. _Molecular Oncology_. 2019. Vol. 13, núm. 9, pàgs. 1827-1835. [consulta: 20 de gener de 2026]. ISSN: 1574-7891. [Disponible a: https://hdl.handle.net/2445/177745]

Exportar metadades

JSON - METS

Compartir registre